Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing... see more

Recent & Breaking News (TSX:MDNA)

Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

GlobeNewswire September 28, 2023

Medicenna to Participate at The H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 6, 2023

Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

GlobeNewswire August 28, 2023

Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management

GlobeNewswire August 14, 2023

Medicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study

GlobeNewswire August 9, 2023

Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee 

GlobeNewswire August 8, 2023

Medicenna Therapeutics to Provide Clinical Update from Phase 1/2 ABILITY Study on August 9, 2023

GlobeNewswire August 4, 2023

Medicenna Therapeutics notches U.S. patent for BiSKIT platform

Jocelyn Aspa August 1, 2023

Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology

GlobeNewswire August 1, 2023

Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights

GlobeNewswire July 28, 2023

Medicenna Presents at National Brain Tumor Society's Research Round Table

GlobeNewswire July 25, 2023

Medicenna Extends Period to Exercise Certain Warrants

GlobeNewswire July 5, 2023

Medicenna Reports Fiscal Year 2023 Financial Results and Operational Highlights

GlobeNewswire June 27, 2023

Medicenna Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement

GlobeNewswire April 27, 2023

Medicenna to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 18, 2023

Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting

GlobeNewswire April 17, 2023

Medicenna Provides Clinical Update from Monotherapy Dose Escalation Portion of Phase 1/2 ABILITY Study

GlobeNewswire March 30, 2023

Medicenna Announces Upcoming Presentation at the AACR Annual Meeting

GlobeNewswire March 15, 2023

Medicenna to Present at the Oppenheimer 33rd Annual Healthcare Conference

GlobeNewswire March 2, 2023

Medicenna Establishes At-the-Market Sales Facility

GlobeNewswire February 17, 2023